Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Gallium-68 DOTATATE - Advanced Accelerator Applications

Drug Profile

Gallium-68 DOTATATE - Advanced Accelerator Applications

Alternative Names: 68Ga-DOTA-TATE; 68Ga-DOTA-tyr3-Octreotate; DOTATATE-Ga68; GA-68 DOTATATE; GalioMedix; NETSPOT; SomaKit TOC; Somakit-TATE

Latest Information Update: 05 Apr 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Advanced Accelerator Applications
  • Developer Advanced Accelerator Applications; Assistance Publique - Hopitaux de Marseille; Centre de recherche du Centre hospitalier universitaire de Sherbrooke; Radio-Isotope Therapy of America Foundation; RadioMedix
  • Class Imaging agents; Organometallic compounds; Radiopharmaceutical diagnostics; Radiopharmaceuticals
  • Mechanism of Action Ionising radiation emitters; Positron-emission tomography enhancers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Neuroendocrine tumours
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Neuroendocrine tumours

Most Recent Events

  • 21 Mar 2024 Phase-III clinical trials in Neuroendocrine tumours (Diagnosis) in Japan (IV) (NCT06240741)
  • 05 Feb 2024 Novartis plans a phase III trial for Neuroendocrine tumors in Japan (IV) in March 2023 (NCT06240741)
  • 11 Nov 2021 Novartis plans a phase I trial in Glioblastoma (Combination therapy, Monotherapy, Recurrent, First line therapy) (NCT05109728), in February 2022
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top